advanced search

Kedalion Therapeutics

Kedalion Therapeutics, a venture-backed, clinical-stage ophthalmic drug delivery company, is developing the AcuStream technology. The device’s horizontal stream delivers topical ocular drugs precisely and accurately, aiming to reduce required dose by 80% compared with standard drops.


HEADQUARTERS
Kedalion Therapeutics, Inc
1490 O’Brien Drive, Suite C
Menlo Park
CA 94025
United States

Phone / Contact

T: +1 650 461 4503

Authors and Contacts

Reynaldo Quintana
Vice-President of Engineering
Kedalion Therapeutics

 

Dr Mark Blumenkranz
Executive Chairman and Co-founder
Kedalion Therapeutics

 

Ehud Ivri
Chief Technology Officer and Co-founder
Kedalion Therapeutics

 

Dr Peter Noymer
Chief Executive Officer
Kedalion Therapeutics

Article

OCULAR
Dr Peter Noymer
ACUSTREAM™: BRINGING TOPICAL OPHTHALMIC DRUG DELIVERY INTO THE MODERN ERA
Peter Noymer, Ehud Ivri, Reynaldo Quintana and Mark Blumenkranz introduce AcuStream, a novel device for next-generation delivery of topical ophthalmic delivery via an aim-assisted stream.
Top

W3 Total Cache is currently running in Pro version Development mode.